Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 13, 2019
June 17, 2019
32f6b565-3151-4e63-8311-63f0e604bece
Related Documents
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentJanuary 6, 2025Center for Drug Evaluation and Research
Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentMay 10, 2018Center for Drug Evaluation and Research
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentJanuary 6, 2025Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox